programmable nanogel platform
for multi-dimensional control
over anticancer drug delivery
Redoxa turns established cytotoxic drugs into targeted formulations. The drug is bound into the carrier, the carrier is aimed at tumour cells, and the payload is only let go once it is inside one.
Doxorubicin is given to more than a million patients a year. It reaches tumour tissue and healthy tissue alike, and that lack of selectivity is what makes its side effects dose-limiting.
Two answers exist today, and each trades one problem for another. Antibody–drug conjugates target well but carry only a handful of drug molecules per antibody and are complex to manufacture. Nanocarriers such as Doxil and Abraxane are simpler to make, but rely on passive accumulation and give little control over when the drug comes out.
Drug molecules are bound covalently into the polymer network rather than trapped in it, so the payload stays put in circulation. A single particle carries on the order of tens of thousands of them — orders of magnitude beyond what an antibody can hold.
Targeting ligands on the particle surface drive receptor-mediated uptake instead of passive accumulation. The platform is target-agnostic; our first product uses vitamin B12 to reach the CD320 receptor, part of a nutrient-uptake pathway that tumours lean on.
The crosslinkers holding the network together are cleaved by the acidity and glutathione levels found inside tumour cells. Over 80% of the drug is released under tumour-like conditions, against around 20% under normal physiological ones.
| Mechanism | ADCs | Nanocarriers | Redoxa |
|---|---|---|---|
| Program the payload | Low payload, 2–8 drugs per antibody | Mostly physical or electrostatic loading | Covalent, high-capacity loading |
| Target the tumor | Active, selective | Often passive accumulation (EPR) | Active, selective, wider range of targets |
| Trigger the release | Cleavable linker | Often passive, gradual release | Tumour-responsive pH and redox release |
TRL 4, moving to TRL 5. Several nanogel chemistries synthesised and characterised, with validated trigger-sensitive release, cancer cell selectivity in vitro, and first in vivo anti-tumour efficacy.
Three patent applications filed around the core platform — P.449342 and P.448586 at the Patent Office of the Republic of Poland, EP254600005.9 at the European Patent Office — covering the nanogel chemistry, covalent drug binding, trigger-sensitive release and active targeting.
The chemistry is in the peer-reviewed literature, including a first-in-class selenocystine-crosslinked nanogel in Chemical Engineering Journal Advances (2026).
Selecting the lead payload–indication pair and completing the translational package: receptor-mediated uptake, biodistribution, tolerability and in vivo efficacy. CMC and scalable manufacturing development runs in parallel.
The science comes out of the Functional Gel Materials Group at the Chemical and Biological Research Centre, University of Warsaw, where the platform has been built and characterised over several years.
Scientific advisors: Felix Zelder and Paula D. Mestizo (University of Zurich), Tomasz S. Kamiński (University of Warsaw). Technology transfer with Rafał Orłowicz-Murawski, University of Warsaw. Company building with Biocatalyst Venture Studio.
Redoxa is being prepared for spin-out. We are open to licensing and co-development conversations with pharma partners, and to talking with investors and collaborators working on targeted delivery.
Mednieku 4a–202